Gilead Sciences Inc (GILD)
66.94
-0.37
(-0.55%)
USD |
NASDAQ |
Apr 17, 16:00
66.94
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 83.39B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -16.80% |
| Valuation | |
| PE Ratio | 14.88 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.105 |
| Price to Book Value | 3.652 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.77 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.094 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 43.18% |
Profile
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology. |
| URL | https://www.gilead.com |
| Investor Relations URL | https://investors.gilead.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Apr. 25, 2024 |
| Last Earnings Release | Feb. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2024 |
Ratings
Profile
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology. |
| URL | https://www.gilead.com |
| Investor Relations URL | https://investors.gilead.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Apr. 25, 2024 |
| Last Earnings Release | Feb. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2024 |